Theodore W. Laetsch, MD
Associate Professor of Pediatrics (Oncology) at the Children's Hospital of Philadelphia
Attending Physician, Division of Oncology, Children's Hospital of Philadelphia
Inaugural Director, Very Rare Malignant Tumors Program, Children's Hospital of Philadelphia
Director, Developmental Therapeutics Program, Children's Hospital of Philadelphia
Co-Leader, Pediatric Oncology Program, Abramson Cancer Center, University of Pennsylvania
Department: Pediatrics
Contact information
Children's Hospital of Philadelphia
HUB for Clinical Collaboration
3500 Civic Center Blvd; Office 3527
Philadelphia, PA 19104
HUB for Clinical Collaboration
3500 Civic Center Blvd; Office 3527
Philadelphia, PA 19104
Email:
laetscht@chop.edu
laetscht@chop.edu
Publications
Education:
BS (Agriculture and Biosystems Engineering)
University of Arizona, Tucson, 2001.
MD
University of California, San Francisco, 2005.
Permanent linkBS (Agriculture and Biosystems Engineering)
University of Arizona, Tucson, 2001.
MD
University of California, San Francisco, 2005.
Selected Publications
Yang AT, Lai ST, Laetsch TW, Bhatti T, Baloch Z, Surrey LF, Franco AT, Ricarte-Filho JCM, Mostoufi-Moab S, Adzick NS, Kazahaya K, Bauer AJ: Molecular landscape and therapeutic strategies in pediatric differentiated thyroid carcinoma. Endocrine Rev 46(3): 397-417, May 2025.Yang AT, Lai ST, Laetsch TW, Bhatti T, Baloch Z, Surrey LF, Franco AT, Ricarte-Filho JCM, Mostoufi-Moab S, Adzick NS, Kazahaya K, Bauer AJ.: Molecular landscape and therapeutic strategies in pediatric differentiated thyroid carcinoma. Endocr Rev 46(3): 397-417, May 2025.
Dela Cruz FS, Fox E, DuBois SG, Friedman GK, Croop JM, Kim A, Morgenstern DA, Balis FM, Macy ME, Pressey JG, Watt T, Krystal JI, Vo KT, Mody R, Laetsch TW, Weigel BJ, O'Hara K, He CS, Aluri J, Okpara CE, Glade Bender JL: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors. Pediatric Blood & Cancer 72(7), May 2025 Notes: doi: 10.1002/pbc.31692.
Hong DS, Xu RH, Shen L, Dierselhuis MP, Orbach D, McDermott R, Italiano A, Tahara M, Bernard-Gauthier V, Neu N, Mussi CE, De La Cuesta E, Laetsch TW, Drilon A: Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer. ESMO Open 10(6), May 2025 Notes: doi: 10.1016/j.esmoop.2025.105110.
Dholaria H, Tsetlina V, Simpson SK, Gillies E, Eswaran N, Rodriguez-Galindo C, Schultz KAP, Chen KS, Wu CC, Krasin MJ, Roemer T, Christiansen H, Piao J, Laetsch TW, Pashankar F, Kontny U, Gartrell RD: One-Two Punch: Combining Chemotherapy and Immunotherapy to Decrease Radiation Dose and Related Toxicity in Children and Adolescents with Nasopharyngeal Carcinoma. Clinical Cancer Research May 2025 Notes: doi: 10.1158/1078-0432.CCR-24-3546.
Gaze MN, Handkiewicz-Junak D, Hladun R, Laetsch TW, Sorge C, Sparks R, Wan S, Ceraulo A, Kluczewska-Galka A, Gámez-Cenzano C, States LJ, El Khouli R, Aimone P, Perraud K, Kollar G, Khanshan F, Blumenstein L, Brouri F, Giraudet AL: Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study. Eur J Nucl Med Mol Imaging Page: doi: 10.1007/s00259-025-07246-7, Apr 2025.
Mascarenhas L, DuBois SG, Albert CM, Bielack S, Orbach D, Federman N, Geoerger B, Nagasubramanian R, Zhang Y, Chisholm J, Gallego Melcon S, Goto H, Morgenstern DA, Owens C, Pappo AS, Perreault S, Schulte JH, Shukla N, Zwaan CM, Neu N, Bernard-Gauthier V, De La Cuesta E, van Tilburg CM, Laetsch TW: Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors. Journal of Clinical Oncology 43(10): 1180-1187, April 2025 Notes: Erratum: 43:10 March 2025, 1046.
Leboulleux S, Boucai L, Busaidy N, Durante C, Fagin JA, Fazeli S, Gianoukakis AG, Haugen BR, Kang H, Konda B, Laetsch TW, Locati L, Ryder M, Spitzweg C, Worden FP, Wirth L, Ho A: Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement. The Lancet Diabetes & Endocrinology 13(6), Apr 2025 Notes: doi: 10.1016/S2213-8587(25)00064-6.
Kothari R, Donner JR, Balakrishnan K, Hartman G; Pediatric Thyroid Program Workgroup:; Alazraki A, Antal Z, Bauer A, Chelius D, Cherella C, Dahl JP, Dimachkieh A, Fox LA, Helmig S, Jiang W, Kazahaya K, Laetsch TW, Lodish M, Mahajan P, Parsons L, Prickett K, Quintanilla-Dieck L, Rastatter J, Rothstein DH, Simons J, Sheyn A, Wagner A, Waguespack SG, Wasserman JD, Wassner AJ, Seeley H, Meister KD: Composition and Priorities of Multidisciplinary Pediatric Thyroid Programs: A Consensus Statement. Thyroid 34(4): 346-356, Apr 2025 Notes: DOI: 10.1089/thy.2024.0496.
Laetsch TW, Voss S, Ludwig K, Hall D, Barkauskas DA, DuBois SG, Ronan J, Rudzinski ER, Memken A, Robinson K, Sorger J, Reid JM, Bhatla T, Crompton BD, Church AJ, Fox E, Weigel BJ: Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823). Journal of Clinical Oncology 43(10): 1188-1197, Apr 2025 Notes: doi: 10.1200/JCO-24-01854.